123 results on '"Karapetis, Christos Stelios"'
Search Results
2. Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: The randomized AGITG DYNAMIC-Rectal study.
3. Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma
4. NABNEC: A randomised phase II study of nab -paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs).
5. SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial
6. First-line anti-EGFR or anti-VEGF therapy, tumour sidedness, and survival: Results from the South Australian (SA) Metastatic Colorectal Cancer (mCRC) Registry.
7. Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.
8. Evaluating the time toxicity of cancer treatment in the CCTG CO.17 randomized clinical trial (RCT).
9. Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
10. Patterns of care and survival of first line anti-EGFR therapy; results from South Australian (SA) metastatic colorectal (mCRC) registry.
11. SPAR: A randomized placebo-controlled phase 2 trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: An AGITG clinical trial.
12. First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).
13. European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions
14. Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry
15. Phase 1 trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study)
16. Phase 1 trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study).
17. Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer
18. Circulating tumor DNA and circumferential resection margin as key prognostic indicators for survival in rectal cancer.
19. Predicting chemotherapy‐induced menopause using baseline and post‐chemotherapy anti‐Müllerian hormone levels: Results of a pilot study
20. Study protocol of a phase 1 clinical trial establishing the safety of intrapleural administration of liposomal curcumin: curcumin as a palliative treatment for malignant pleural effusion (IPAL-MPE)
21. Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer.
22. Identifying biomarkers to guide immunotherapy treatment of cancer of unknown primary.
23. Phase I trial of nab-paclitaxel administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma (ART in LAP).
24. Regorafinib outcomes from the population-based South Australian mCRC registry (SAmCRCR).
25. Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.
26. Prognostic differences of RAS mutations: Results from South Australian (SA) metastatic colorectal (mCRC) registry.
27. MONARCC: A randomized phase II study of panitumumab monotherapy and panitumumab (pan) plus 5 Fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer (mCRC): An AGITG clinical trial.
28. Gemcitabine and reactivation of hepatitis B
29. Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival
30. Patient reported outcome measures (PROMs) in patients (pts) with locally advanced rectal cancer (LARC) managed with a watch and wait (W&W) approach after a clinical complete response to chemoradiotherapy (CRT).
31. Phase 1 open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases.
32. A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).
33. Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.
34. A prospective study of anti-mullerian hormone (AMH) as a predictor of chemotherapy-induced menopause.
35. Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.
36. Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.
37. Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol
38. The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study.
39. Metastatic colorectal cancer (mCRC) and micro-satellite instability.
40. Phase I open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases.
41. Outcomes for metastatic colorectal cancer (mCRC) based on microsatellite instability.
42. AGITG nabnec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.
43. The utility of genomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: The PREDICT IR study.
44. Bevacizumab and its impact on survival for patients receiving subsequent anti-EGFR therapy: Updated results from the SA metastatic CRC registry.
45. Age as a predictive and prognostic factor for targeted therapy treatment in metastatic chemorefractory colorectal cancer (CRC): An analysis of NCIC CTG CO.17 and CO.20.
46. Outcomes of solid tumor malignancies in patients of Jehovah’s Witness faith.
47. The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern.
48. Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.
49. Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).
50. Nonagenarian patients with metastatic colorectal cancer: Results from the South Australian metastatic colorectal cancer registry.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.